Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 79.96M | 81.67M | 96.63M | 74.86M | 54.92M | 42.44M |
Gross Profit | 49.37M | 47.88M | 56.30M | 43.39M | 34.22M | 25.91M |
EBITDA | -31.79M | -37.14M | -45.63M | -58.81M | -35.17M | -10.13M |
Net Income | -47.53M | -55.37M | -63.32M | -70.64M | -42.94M | -16.71M |
Balance Sheet | ||||||
Total Assets | 112.65M | 125.00M | 180.37M | 176.03M | 190.91M | 77.66M |
Cash, Cash Equivalents and Short-Term Investments | 27.54M | 35.04M | 83.13M | 81.22M | 113.08M | 17.01M |
Total Debt | 83.72M | 84.15M | 85.71M | 75.78M | 32.47M | 34.99M |
Total Liabilities | 118.54M | 117.41M | 126.60M | 117.45M | 69.56M | 59.09M |
Stockholders Equity | -5.89M | 7.59M | 53.77M | 58.58M | 121.35M | 18.57M |
Cash Flow | ||||||
Free Cash Flow | -32.34M | -46.56M | -54.55M | -60.86M | -41.16M | -10.14M |
Operating Cash Flow | -30.49M | -44.10M | -50.90M | -53.50M | -36.07M | -6.84M |
Investing Cash Flow | 40.81M | -24.05M | 3.35M | -14.08M | -5.09M | 6.73M |
Financing Cash Flow | -3.01M | -3.21M | 56.84M | 28.73M | 137.03M | 5.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
52 Neutral | $105.82M | ― | -78.93% | ― | -70.15% | ― | |
49 Neutral | $64.44M | ― | -354.27% | ― | -14.55% | 34.87% | |
44 Neutral | $97.17M | ― | -122.69% | ― | ― | 20.91% | |
36 Underperform | $97.52M | ― | -55.68% | ― | ― | -57.45% | |
36 Underperform | $43.58M | ― | -62.41% | ― | ― | 10.84% |
On July 8, 2025, Akoya Biosciences, a company involved in a merger, repaid all outstanding obligations under its Credit Agreement and terminated its Employee Stock Purchase Plan and Equity Distribution Agreement. The merger resulted in the conversion of Akoya’s common stock into Quanterix shares and cash, adjustments to stock options and restricted stock units, and significant changes in Akoya’s board and executive officers. Akoya also requested the suspension of its stock trading on Nasdaq and plans to terminate its stock registration and reporting obligations.
The most recent analyst rating on (AKYA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Akoya Biosciences stock, see the AKYA Stock Forecast page.
On April 28, 2025, Akoya Biosciences and Quanterix Corporation amended their merger agreement, initially announced on January 9, 2025. Under the revised terms, Quanterix will issue approximately 7.76 million shares and pay $20 million in cash to Akoya shareholders, with each Akoya share receiving $0.38 in cash and 0.1461 shares of Quanterix stock. This adjustment reduces the number of shares issued by Quanterix compared to the original agreement. The merger, expected to close in the second quarter of 2025, aims to create significant value for shareholders and leverage synergies across both organizations.